AstraZeneca invests $2 billion in Summit Therapeutics in cancer drug deal

{
  "signal_id": "8ea7b5ce-c366-71c1-acd0-f775462a415a",
  "signal_type": "news",
  "signal_subtype": "partners_with",
  "detected_at": "2026-09-29T06:38:27+00:00",
  "company": {
    "name": "AstraZeneca",
    "domain": "astrazeneca.com"
  },
  "data": {
    "url": "https://www.proactiveinvestors.com/companies/news/1099267/astrazeneca-invests-2-billion-in-summit-therapeutics-in-cancer-drug-deal-1099267.html",
    "title": "AstraZeneca invests $2 billion in Summit Therapeutics in cancer drug deal - proactiveinvestors.com",
    "excerpt": "Ephrem began his journalistic journey at Proactive in June 2021. With a strong academic background in Information Technology, his expertise particularly lies in the field of Cyber Security, Management Information Systems and Computer Forensics. Before joining Proactive, Ephrem worked as a researcher and lecturer at a number of leading universities, including the University of Portsmouth's Institute of Criminal Justice Studies, the University of Winchester’s Institute of Policing, and Jain... Read more Proactive financial news and online broadcast teams provide fast, accessible, informative and actionable business and finance news content to a global investment audience. All our content is produced independently by our experienced and qualified teams of news journalists. Proactive news team spans the world’s key finance and investing hubs with bureaus and studios in London, New York, Toronto, Vancouver, Sydney and Perth. We are experts in medium and small-cap markets, we also keep our community up to date with blue-chip companies, commodities and broader investment stories. This is content that excites and engages motivated private investors. The team delivers news and unique insights across the market including but not confined to: biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto and emerging digital and EV technologies. Proactive has...",
    "summary": "AstraZeneca and Summit Therapeutics will begin clinical trials combining Summit’s ivonescimab with AstraZeneca’s sonesitatug vedotin in gastrointestinal cancers.",
    "planning": true,
    "image_url": "https://cdn.proactiveinvestors.com/eyJidWNrZXQiOiJwYS1jZG4iLCJrZXkiOiJ1cGxvYWRcL05ld3NcL0ltYWdlXC8yMDI2XzA5XC9kcnVncy1hc3RyYXplbmVjYS5qcGVnIiwiZWRpdHMiOnsicmVzaXplIjp7IndpZHRoIjoxMjAwLCJoZWlnaHQiOjYzMCwiZml0IjoiY292ZXIifX19",
    "confidence": 1,
    "published_at": "2026-09-29T06:38:27Z",
    "article_sentence": "The companies will also begin clinical trials combining Summit’s ivonescimab with AstraZeneca’s sonesitatug vedotin in gastrointestinal cancers.",
    "related_company_name": "Summit Therapeutics Inc.",
    "related_company_domain": "summittxinc.com"
  }
}

curl https://signals.autobound.ai/v1/signals/8ea7b5ce-c366-71c1-acd0-f775462a415a \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"astrazeneca.com","limit":20}'